Transforming Your Capabilities.
We provide the seamless integration of GI research into your practice to broaden your offerings, enhance care for your patients, and increase your support for referring physicians.
Transforming Your Research.
With premier integrated research partnerships across the country, we can offer a program supported by embedded study teams, leading to greater patient access at the point of care.
Transforming Your Outlook.
We are studying NASH and other diseases with the aim of developing new therapies to address growing problems and improve your overall health.
Let’s work together.
We’re taking on NASH with strong research partnerships and innovative approaches that leverage a proven platform. You can be part of it.
Our gut microbes influence our reactions to medications, new research shows.
A number of studies have found that certain strains of bacteria within a patient’s microbiome can impact their body’s response to medication – in both positive and negative ways. Read more to learn about these discoveries.
Evidence in favor of blood testing shows new technology surpassing anticipated milestones.
Despite past fraudulent claims about this technology from Theranos – the now-infamous and defunct healthcare company – blood testing capabilities are fast outpacing previous predictions in the medical field. Take a look at this FierceBiotech article to learn more.
Hydrogel pill for overweight or obese patients approved by FDA.
In 2019, the FDA approved the Gelesis100 oral hydrogel pill therapy for weight management. This capsule induces a feeling of fullness to help patients control their hunger without the drawback of added calories. Read more about this first-of-its-kind hydrogel pill therapy.
ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures
Contacts:Colleen Hoke, ObjectiveGI firstname.lastname@example.orgJillian Hammell, Crowley Webbjillian.email@example.com x237 ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic NASHVILLE, TN, December 20, 2019 – ObjectiveGI, the integrated research and technology services platform company, announced today ...